Lantheus culls late-stage Lilly-partnered prostate cancer radioligand
Lantheus finally came clean about the fate of its experimental radiopharmaceutical for prostate cancer, confirming Wednesday that it has dropped the asset. The company had licensed the β-emitter, known as PNT2002, from Point Biopharma ...
Lantheus finally came clean about the fate of its experimental radiopharmaceutical for prostate cancer, confirming Wednesday that it has dropped the asset.
The company had licensed the β-emitter, known as PNT2002, from Point Biopharma ...
